Equities researchers at StockNews.com assumed coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a research report issued on Wednesday. The brokerage set a "hold" rating on the stock.
NantHealth Trading Down 0.6 %
Shares of NASDAQ NH opened at $3.13 on Wednesday. NantHealth has a twelve month low of $1.57 and a twelve month high of $15.75. The stock has a fifty day simple moving average of $2.41 and a 200-day simple moving average of $1.11. The stock has a market capitalization of $24.13 million, a PE ratio of -0.41 and a beta of 1.96.
Get
NantHealth alerts:
NantHealth (NASDAQ:NH – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter. The firm had revenue of $16.63 million during the quarter.
Institutional Investors Weigh In On NantHealth
A number of institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new position in shares of NantHealth during the 2nd quarter worth $36,000. Millennium Management LLC purchased a new position in shares of NantHealth in the 2nd quarter worth $110,000. Atria Wealth Solutions Inc. raised its position in shares of NantHealth by 117.7% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 491,942 shares of the company's stock worth $205,000 after buying an additional 265,949 shares during the period. Finally, Hartline Investment Corp purchased a new position in shares of NantHealth in the 2nd quarter worth $65,000. Institutional investors and hedge funds own 4.50% of the company's stock.
NantHealth Company Profile
(Get Rating)
NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.
Read More
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com的股票研究人員假設了NantHealth(納斯達克：NH-GET評級)在週三發佈的一份研究報告中。該經紀公司對該股設定了“持有”評級。
NantHealth股價下跌0.6%
週三，納斯達克NH的股價開盤報3.13美元。NantHealth的12個月低點為1.57美元，12個月高位為15.75美元。該股的50日簡單移動均線為2.41美元，200日簡單移動均線為1.11美元。該股市值為2,413萬美元，本益比為-0.41，貝塔係數為1.96。
到達
NantHealth警報：
NantHealth(納斯達克：NH-GET評級)最近一次發佈季度收益數據是在11月3日星期四。該公司公佈了該季度每股收益(EPS)(0.13美元)。該公司本季度的收入為1663萬美元。
機構投資者看好NantHealth
一些機構投資者和對沖基金最近調整了對該公司的持股。高盛股份有限公司在第二季度購買了價值36,000美元的南洋健康新股頭寸。Millennium Management LLC在第二季度購買了價值11萬美元的NantHealth新股頭寸。Atria Wealth Solutions Inc.在第二季度將其在NantHealth的股票頭寸提高了117.7%。Atria Wealth Solutions Inc.在此期間又購買了265,949股Atria Wealth Solutions Inc.，目前持有491,942股該公司股票，價值20.5萬美元。最後，Hartline Investment Corp在第二季度購買了價值6.5萬美元的NantHealth股票的新頭寸。機構投資者和對沖基金持有該公司4.50%的股票。
NantHealth公司簡介
(獲取評級)
NantHealth，Inc.是一家以證據為基礎的個性化保健公司，致力於為癌症等危重疾病提供治療。該公司支持治療決策，改善患者結局，驗證治療選項，實現高質量護理，降低成本，確保適當的報銷，並簡化實施和部署。
閱讀更多內容
- 免費獲取StockNews.com關於NantHealth(NH)的研究報告
- Verizon，Charge在過去的一個月裡趨勢更高：他們現在購買嗎？
- 股利之王Sysco：逢低買入
- 天才集團股票1600%的漲幅合理嗎？
- 在進一步審查後，投資者喜歡埃克森美孚的收益
- 卡特彼勒會挖出另一個收購機會嗎？
接受《NantHealth Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對NantHealth和相關公司的最新新聞和分析師評級的每日簡要摘要。
